Omeprazole Side Effects in Children
Omeprazole is generally well tolerated in children, but clinicians must monitor for specific adverse effects including headache, abdominal pain, diarrhea, nausea, respiratory infections, and rare but serious complications such as hypomagnesemia, vitamin B12 deficiency, and increased infection risk, particularly with long-term use.
Common Side Effects
The most frequently reported adverse effects in pediatric patients include 1, 2:
- Headache (7%)
- Abdominal pain (5%)
- Nausea (4%)
- Diarrhea (4%)
- Vomiting (3%)
- Flatulence (3%)
Pediatric-Specific Adverse Effects
Children aged 2-16 years experience unique side effects not commonly seen in adults 2:
- Respiratory system events (19% in the 2-16 year age group) - this is the most notable pediatric-specific finding
- Fever
- Accidental injuries (4%)
Serious Adverse Effects Requiring Monitoring
Electrolyte Disturbances
Hypomagnesemia is a critical concern with prolonged PPI use 1, 2, 3:
- Typically occurs after ≥3 months of continuous use, usually after 1 year of treatment
- May be asymptomatic in children 3
- When symptomatic, presents with: seizures, jitteriness, muscle spasms, tremors, abnormal heart rhythms, muscle weakness
A 2020 study specifically in children demonstrated that omeprazole can cause asymptomatic hypomagnesemia, hypocalcemia, and hypernatremia after just 4 weeks of use 3. This suggests earlier monitoring may be warranted in pediatric populations than previously recognized.
Recommendation: Check magnesium levels before initiating long-term therapy and periodically during treatment, particularly after 3 months 2.
Vitamin B12 Deficiency
Long-term use (>3 years) reduces stomach acid needed for B12 absorption 1, 2. The FDA drug label specifically warns about this risk and recommends discussing B12 deficiency possibility with patients on prolonged therapy 2.
Increased Infection Risk
Critical concern in infants: PPIs increase risk of lower respiratory tract infections, particularly in the youngest patients 1. The 2013 AAP guidelines specifically caution against PPI overuse in infants, noting that placebo-controlled trials in infants have not demonstrated superiority of PPIs over placebo for reducing irritability 1.
Additional infection risks include 1:
- Community-acquired pneumonia
- Gastroenteritis
- Candidemia
- Necrotizing enterocolitis in preterm infants
Bone Health
Fundic gland polyps develop in up to 50% of children receiving PPIs for >2.5 years 1. While considered benign histologically, this represents a significant structural change requiring awareness.
Bone fractures: FDA labeling includes warnings about increased fracture risk, though data are primarily from adult studies 4, 2.
Rare but Documented Adverse Effects
- Psychotic symptoms: A case report documented formal thought disorder and delusional ideas in a 12-year-old that resolved immediately upon discontinuation 5
- Dry mouth: Can predispose to opportunistic infections, particularly Candida albicans 6
- Allergic reactions: Rash, throat tightness, face swelling, difficulty breathing 2
Long-Term Safety Data
Reassuring evidence exists for extended use: A 2007 study of 166 children using PPIs continuously for up to 11.25 years (median 3 years) found only 6 adverse reactions in 4 patients potentially related to PPIs (nausea, diarrhea, rash, agitation, irritability), with drug discontinuation rarely indicated 7. However, this predates current understanding of electrolyte disturbances and infection risks.
Critical Clinical Pitfalls
Overuse in infants with reflux: The guidelines strongly caution that PPIs are no better than placebo for infant irritability attributed to reflux 1
Failure to monitor electrolytes: Given the 2020 data showing electrolyte changes as early as 4 weeks 3, baseline and periodic monitoring is essential
Ignoring respiratory symptoms: The high rate (19%) of respiratory events in children requires vigilance 2
Assuming adult safety profiles apply: Children have unique adverse effect patterns, particularly respiratory complications
FDA-Approved Dosing and Age Indications
Omeprazole is FDA-approved for children 2-16 years of age at doses of 0.7-3.3 mg/kg/day 1. The capsule contents can be sprinkled on soft foods for ease of administration 1, 2.
The evidence supports that omeprazole can be used safely in children when appropriately indicated, but requires more vigilant monitoring than in adults, particularly for electrolyte disturbances, respiratory complications, and infection risk.